Tau Immunotherapies for Neurodegenerative Diseases

Tau Immunotherapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Immunotherapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab) (BAN2401)</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab) (LY3002813)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Aduanemab</td>
<td>Prothena/Roche</td>
</tr>
<tr>
<td class="label">Gosutromab (BMS-986168)</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105705)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">JNJ-63773257</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">E2027</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune/Lilly</td>
</tr>
<tr>
<td class="label">AXON vaccines</td>
<td>Axon Neuroscience</td>
</tr>
<tr>
<td class="label">AADvac1</td>
<td>Axon Neuroscience</td>
</tr>
<tr>
<td class="label">Davunetide (NAP)</td>
<td>Allon Therapeutics</td>
</tr>
<tr>
<td class="label">ACI-35.04</td>
<td>AC Immune</td>
</tr>
</table>

Tau Immunotherapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Immunotherapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab) (BAN2401)</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab) (LY3002813)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Aduanemab</td>
<td>Prothena/Roche</td>
</tr>
<tr>
<td class="label">Gosutromab (BMS-986168)</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Semorinemab (RO7105705)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">JNJ-63773257</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">E2027</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune/Lilly</td>
</tr>
<tr>
<td class="label">AXON vaccines</td>
<td>Axon Neuroscience</td>
</tr>
<tr>
<td class="label">AADvac1</td>
<td>Axon Neuroscience</td>
</tr>
<tr>
<td class="label">Davunetide (NAP)</td>
<td>Allon Therapeutics</td>
</tr>
<tr>
<td class="label">ACI-35.04</td>
<td>AC Immune</td>
</tr>
</table>

Tau Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

[Tau](/proteins/tau) immunotherapies represent one of the most advanced disease-modifying approaches for tauopathies, targeting the pathological accumulation and spread of hyperphosphorylated [tau protein](/proteins/tau) in the brain. These therapies aim to reduce neurofibrillary tangle formation and slow the progression of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other tauopathies. [@sims2023]

Mechanism of Action

Tau immunotherapies work through several mechanisms to clear pathological tau: [@mullard2024]

Passive Immunization

• Anti-tau monoclonal antibodies bind extracellular tau aggregates
• Promote Fc-mediated microglial clearance of toxic species
• Block neuron-to-neuron propagation of tau pathology
• May enter [neurons](/entities/neurons) via receptor-mediated endocytosis

Active Immunization

• Tau vaccines stimulate endogenous antibody production
• Target specific tau epitopes (phosphorylated, truncation, conformational)
• Elicit antibodies against extracellular tau oligomers and fibrils
• Long-lasting immunity with periodic boosters

Key Tau Epitopes Targeted

• pSer396/pSer404 (PHF-tau epitopes)
• pThr231 (early phosphorylation marker)
• N-terminal fragments (e.g., aa 6-15, 15-25)
• Mid-domain regions (e.g., aa 184-238)
• C-terminal fragments (e.g., aa 368-378)

Clinical Candidates

Passive Immunotherapies (Anti-Tau Antibodies)

Active Immunotherapies (Tau Vaccines)

Disease-Specific Applications

Alzheimer's Disease

• Lecanemab (Leqembi): Approved for early AD (MCI due to AD, mild AD dementia)
• Donanemab: Approved for early AD (MCI, mild dementia)
• Target patients with amyloid positivity (PET or CSF)
• May benefit from tau PET positivity
• Combination with amyloid-lowering therapies under study

Progressive Supranuclear Palsy (PSP)

• Gosutromab: Targeted 4R tau pathology
• Phase II TANGO trial in PSP patients
• Showed reduced tau burden in secondary analyses
• Biomarker: CSF tau, tau PET

Corticobasal Degeneration (CBD)

• Similar approach to PSP (4R tau)
• Fewer clinical trials due to disease rarity
• Antibody approaches may need to address both neuronal and glial pathology

Other Tauopathies

• Chronic Traumatic Encephalopathy (CTE): Active investigation
• Primary Age-Related Tauopathy (PART): Theoretical benefit
• Pick's Disease: 3R tau - may require specific epitopes

Clinical Trial Results

Lecanemab (Clarity AD)

• Primary endpoint met: Slowed cognitive decline by 27% (CDR-SB)
• Reduced amyloid plaque by 55 centiloids at 18 months
• Reduced tau accumulation on PET
• ARIA-E incidence: 12.6% (vs 1.7% placebo)
• Approved January 2023

Dononemab (TRAILBLAZER-ALZ 2)

• Primary endpoint met: 35% slower decline (iADRS)
• 36% slower decline on CDR-SB
• Reduced amyloid by 84 centiloids at 76 weeks
• ARIA-E incidence: 24% (vs 2.1% placebo)
• Approved July 2024

Gosutromab (TANGO - PSP)

• Primary endpoint not met (PSP Rating Scale)
• Post-hoc analysis showed reduced brain tau on PET
• Favorable safety profile
• Further development for AD ongoing

AADvac1 (AD)

• Phase II showed anti-tau antibody generation
• Reduced rate of cognitive decline in seropositive patients
• Good safety and tolerability
• Phase II extension ongoing

Safety Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

• ARIA-E (edema): Brain edema, microhemorrhages
• ARIA-H (hemorrhage): Cerebral microhemorrhages
• Risk factors: [ApoE](/proteins/apoe-protein) ε4 homozygous, older age
• Monitoring: MRI at baseline, 5th, 12th infusions

Other Adverse Effects

• Infusion-related reactions (usually mild)
• Headache
• Upper respiratory infections

Combination Approaches

Current Research

• Anti-amyloid + anti-tau combination therapy
• Tau immunotherapy + neuroinflammation modulators
• Combined with microglial targeting ([TREM2](/proteins/trem2-protein) agonists)
• Adjunct to cognitive enhancers

See Also

• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Amyloid-Tau Interaction Pathway](/mechanisms/amyloid-tau-convergence)
• [α-Synuclein Immunotherapies](/therapeutics/alpha-synuclein-immunotherapies)
• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Tau Immunotherapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;